TIDM0A45
Moderna Inc
30 March 2023
Moderna Finalizes Agreement with the Government of the Republic
of Kenya to Establish an mRNA Manufacturing Facility
Facility to enable access to manufactured mRNA vaccines for
Kenya and the African continent, providing health security and
building upon Moderna's global public health commitments
The facility will be capable of producing up to 500 million
doses each year
CAMBRIDGE, MA & NAIROBI, KENYA/ ACCESSWIRE / March 30, 2023
/ Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, and the Government
of the Republic of Kenya have finalized an agreement to establish
an mRNA manufacturing facility in the Republic of Kenya. This will
be the Company's first mRNA manufacturing facility in Africa.
In partnership with the Government of the Republic of Kenya,
Moderna will build a state-of-the-art mRNA facility in Kenya to
produce up to 500 million doses of vaccines each year. The Company
expects the new facility to enable drug substance and drug product
manufacturing for Kenya and the African continent. In addition,
this facility will have surge capacity to rapidly scale and respond
to public health emergencies on the continent and around the
world.
"The finalization of our agreement with the Government of the
Republic of Kenya is a key pillar of our global public health
strategy, where we hope to bring mRNA innovation to the people of
Africa in areas of high unmet need, such as acute respiratory
infections, as well as persistent infectious diseases like HIV and
outbreak threats such as Zika and Ebola," said Stéphane Bancel,
Chief Executive Officer of Moderna. "This also demonstrates our
confidence in the investment climate in Kenya and the importance of
utilizing mRNA technology to build resilience in healthcare
security in Africa. We are also grateful for the leadership of the
U.S. Ambassador to Kenya, Meg Whitman, and Samantha Power, in her
role as Administrator of the United States Agency for International
Development for their instrumental support of this project."
"We are excited about this milestone that brings to bear our
efforts as Government to sustain our economic model of facilitating
investments that serve not only Kenya but the African continent. My
Government commits to supporting this investment as a critical
signal to the investment community that Kenya is open for
business," said President William Ruto.
"This investment creates the momentum to meet the $10 billion
annual target under the Government's manufacturing 20 by 30 vision,
where we plan to grow the contribution of manufacturing to GDP to
20% by the year 2030 from the current 7%," said Kenya's Cabinet
Secretary for Investments, Trade, and Industry Hon. Moses
Kuria.
The Government of Kenya has championed an accelerated investment
agenda to grow foreign direct investment levels from the current
levels of $448 million annually to $10 billion annually, making the
country's goal the continent's most ambitious agenda to attract
investments as an enabler to job creation. Moderna's investment
signifies confidence in the business environment in Kenya and
readiness to support foreign and local investment in the healthcare
sector, as well as Moderna's ongoing commitment to global public
health. Moderna will operate under a Special Economic Zone (SEZ)
status, signifying Kenya's increasing focus on the SEZ program as a
key enabler of economic growth.
With this agreement, Moderna has commitments to establish mRNA
manufacturing facilities in Kenya, the United States, Canada,
Australia, and the United Kingdom, furthering health security
around the world. Moderna has spent more than a decade refining its
mRNA platform to accelerate the pace and success of mRNA medicines.
The speed, scale, and flexibility of Moderna's mRNA platform is
uniquely suited for rapid response to serious international
epidemics, commonly referred to as Disease X.([i])
Moderna is committed to advancing into clinical studies a
portfolio of 15 vaccine programs targeting emerging or neglected
infectious diseases by 2025, advancing vaccines that address
current diseases of significant impact to low- and middle-income
countries, and those that prepare for Disease X. Moderna will
prioritize development efforts against pathogens identified as
persistent global health threats, including HIV, tuberculosis (TB)
and malaria, neglected tropical diseases and the priority pathogens
of the World Health Organization and the Coalition for Epidemic
Preparedness Innovations. Learn more at
https://www.modernatx.com/responsibility/our-commitment.
About Moderna
In over 10 years since its inception, Moderna has transformed
from a research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across seven modalities, a
broad intellectual property portfolio, and integrated manufacturing
facilities that allow for rapid clinical and commercial production
at scale. Moderna maintains alliances with a broad range of
domestic and overseas government and commercial collaborators,
which has allowed for the pursuit of both groundbreaking science
and rapid scaling of manufacturing. Most recently, Moderna's
capabilities have come together to allow the authorized use and
approval of one of the earliest and most effective vaccines against
the COVID pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology, and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases, and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past eight years. To
learn more, visit www.modernatx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including statements regarding: the Company's
plans to build an mRNA manufacturing facility in Kenya; the
anticipated capacity and output for that facility; the ability of
the facility to respond to public health emergencies; Moderna's
aspiration to develop treatments or vaccines against HIV, Zika,
Ebola, and other public health pathogens; the ability of Moderna's
mRNA platform to respond to future epidemics; foreign investment in
the health sector in Kenya; the advantages of doing business in a
Kenyan Special Economic Zone; and Moderna's plans to establish
manufacturing facilities in the United State, Canada, United
Kingdom, and Australia. In some cases, forward-looking statements
can be identified by terminology such as "will," "may," "should,"
"could," "expects," "intends," "plans," "aims," "anticipates,"
"believes," "estimates," "predicts," "potential," "continue," or
the negative of these terms or other comparable terminology,
although not all forward-looking statements contain these words.
The forward-looking statements in this press release are neither
promises nor guarantees, and you should not place undue reliance on
these forward-looking statements because they involve known and
unknown risks, uncertainties, and other factors, many of which are
beyond Moderna's control and which could cause actual results to
differ materially from those expressed or implied by these
forward-looking statements. These risks, uncertainties, and other
factors include, among others, those risks and uncertainties
described under the heading "Risk Factors" in Moderna's Annual
Report on Form 10-K for the fiscal year ended December 31, 2022 and
in subsequent filings made by Moderna with the U.S. Securities and
Exchange Commission (SEC), which are available on the SEC's website
at www.sec.gov. Except as required by law, Moderna disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on Moderna's current
expectations and speak only as of the date of this press
release.
Moderna Contacts:
Media:
Luke Mircea Willats
Senior Director, Corporate Communications
Luke.Mirceawillats@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
([i]) "Disease X" was named by the WHO to represent the
knowledge that a serious international epidemic could be caused by
a pathogen currently unknown to cause human disease.
https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts
SOURCE: Moderna, Inc.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAUROWROWUOORR
(END) Dow Jones Newswires
March 30, 2023 07:00 ET (11:00 GMT)
Moderna (LSE:0A45)
Historical Stock Chart
From Jun 2024 to Jul 2024
Moderna (LSE:0A45)
Historical Stock Chart
From Jul 2023 to Jul 2024